FDA advisory highlights supplement excipient
This article was originally published in The Tan Sheet
Executive Summary
One lot of crospovidone from Chinese firm Tianjin Boai NKY International contains peroxide levels more than four times higher than the maximum set by global standards, FDA says Oct. 21. Although not a significant health risk, the peroxide could cause a loss of potency in dietary supplements and pharmaceuticals that use crospovidone and other providone analogues, the agency says. Daniel Fabricant, VP of scientific and regulatory affairs for the Natural Products Association, said the excipient aids dissolution in tablets and softgels, and the high peroxide levels likely signal ingredients past their shelf life expiry. FDA's advisory reminds supplement makers "it's another spec they need to be looking for" in their excipients, Fabricant said
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.